
ViiV Study: 90% Prefer Long-Acting Cabotegravir Over Lenacapavir After One Dose
ViiV Healthcare’s CLARITY Study Highlights Patient and Healthcare Professional Preference for Long-Acting Cabotegravir Over Lenacapavir ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer and Shionogi as shareholders, has released new findings from the phase I CLARITY…













